weight loss drug news today glp-1 october 2025 obesity Outlook for obesity in 2025: more than a transition year Oprah joins wave of celebrities
Description
The more cautious interpretation is that patients who receive GLP-1 receptor agonists may differ in important but incompletely measured ways from those treated with insulin or metformin, including overall health, treatment access, healthcare follow-up, or cardiometabolic care intensity
95% CI [4.110.4]
Evidence & References Medicare GLP-1 Bridge
Research on GLP-1 receptor agonists has shown promising results in reducing alcohol consumption in preclinical and clinical studies
17-hydroxylase (CYP17A1), the rate-limiting enzyme in androgen biosynthesis, is modulated by PKA and MAPK-dependent phosphorylation
